Trial reportBlood2019
Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure.
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01758042 (Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Kidney transplantation in multiple myeloma: patient selection, timing, and post-transplant challenges in the modern therapeutic era.Clinical kidney journal · 2026Review
- Immune reset: what do we learn from bone marrow transplantation.Medical review (2021) · 2026Review
- Review
- Preclinical and clinical studies on kidney allograft tolerance via hematopoietic chimerism.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Review
- Selective impact on regulatory T cells with sustained functional phenotypes by the interleukin-2 mutein VIS171 in a nonhuman primate model.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia.The oncologist · 2026Article
- Cytokines in transplantation tolerance.Best practice & research. Clinical haematology · 2025Review
- Chimerism and immunological tolerance in solid organ transplantation.Seminars in immunopathology · 2025Review
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases.Kidney medicine · 2024Article
- Twenty years in the making: tolerance in a living-related kidney transplant recipient.Journal of nephrology · 2024Article
- Combined Haploidentical Hematopoetic Stem Cell Transplantation and Liver Transplantation in a Pediatric Patient.International journal of hematology-oncology and stem cell research · 2023Article
- Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD).Bone marrow transplantation · 2023Article
- Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment.Frontiers in oncology · 2023Article
- Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.Experimental hematology & oncology · 2022Article
- Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure.Leukemia research reports · 2022Article
- Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4Frontiers in immunology · 2022Article
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).Bone marrow transplantation · 2021Article
- Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice.The Journal of clinical investigation · 2020Article
- Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application.Frontiers in immunology · 2019Review
- Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
At Massachusetts General Hospital, we pioneered simultaneous hematopoietic cell (HCT)/kidney transplantation from HLA-identical related donors for the treatment of hematological malignancies with end-stage renal failure. We have now extended this to HLA-haploidentical donors in a pilot trial. Six recipients, 5 of whom were conditioned with fludarabine, cyclophosphamide, and total-body irradiation, underwent combined HCT/kidney transplantation from haploidentical donors; graft-versus-host disease (GVHD) prophylaxis included post-HCT cyclophosphamide, tacrolimus, and mycophenolate mofetil. One patient died as a result of complications of fludarabine neurological toxicity. No neurological toxicity was observed in subsequent patients who received lower fludarabine doses and more intense postfludarabine dialysis. There were no cases of grade 2 to 4 acute GVHD and 1 case of moderate chronic GVHD by 12 months. One patient experienced relapse of multiple myeloma at 30 months after HCT and died 4 years posttransplantation. Overall, 4 of 6 patients remain alive, without disease relapse and with long-term renal rejection-free survival. This trial was registered at www.clinicaltrials.gov as #NCT01758042.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.